Deborah A. Smith

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

Alex Straumann, Sébastien Conus, Pascale Grzonka et al. · Gut · 2009 · 589 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

Amal Assa’ad, Sandeep K. Gupta, Margaret H. Collins et al. · Gastroenterology · 2011 · 431 citations · Full text

Life Sciences, Immunology, Pediatrics +16

Role of the Hog1 Stress-activated Protein Kinase in the Global Transcriptional Response to Stress in the Fungal Pathogen<i>Candida albicans</i>

Brice Enjalbert, Deborah A. Smith, Michael Cornell et al. · Molecular Biology of the Cell · 2005 · 382 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 365 citations · Full text

Medicine, Oncology, Pharmacology +17